182 related articles for article (PubMed ID: 22986524)
1. EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.
Granit RZ; Gabai Y; Hadar T; Karamansha Y; Liberman L; Waldhorn I; Gat-Viks I; Regev A; Maly B; Darash-Yahana M; Peretz T; Ben-Porath I
Oncogene; 2013 Aug; 32(33):3886-95. PubMed ID: 22986524
[TBL] [Abstract][Full Text] [Related]
2. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Wu J; Crowe DL
Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
[TBL] [Abstract][Full Text] [Related]
3. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
[TBL] [Abstract][Full Text] [Related]
4. Repression of Igf1 expression by Ezh2 prevents basal cell differentiation in the developing lung.
Galvis LA; Holik AZ; Short KM; Pasquet J; Lun AT; Blewitt ME; Smyth IM; Ritchie ME; Asselin-Labat ML
Development; 2015 Apr; 142(8):1458-69. PubMed ID: 25790853
[TBL] [Abstract][Full Text] [Related]
5. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity.
Kim J; Villadsen R; Sørlie T; Fogh L; Grønlund SZ; Fridriksdottir AJ; Kuhn I; Rank F; Wielenga VT; Solvang H; Edwards PA; Børresen-Dale AL; Rønnov-Jessen L; Bissell MJ; Petersen OW
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6124-9. PubMed ID: 22454501
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?
Shen Z; Chen L; Yang X; Zhao Y; Pier E; Zhang X; Yang X; Xiong Y
Biochim Biophys Acta; 2013 Oct; 1833(10):2190-200. PubMed ID: 23688634
[TBL] [Abstract][Full Text] [Related]
7. Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool.
Michalak EM; Nacerddine K; Pietersen A; Beuger V; Pawlitzky I; Cornelissen-Steijger P; Wientjens E; Tanger E; Seibler J; van Lohuizen M; Jonkers J
Stem Cells; 2013 Sep; 31(9):1910-20. PubMed ID: 23712803
[TBL] [Abstract][Full Text] [Related]
8. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity.
Yin J; Leavenworth JW; Li Y; Luo Q; Xie H; Liu X; Huang S; Yan H; Fu Z; Zhang LY; Zhang L; Hao J; Wu X; Deng X; Roberts CW; Orkin SH; Cantor H; Wang X
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15988-93. PubMed ID: 26668377
[TBL] [Abstract][Full Text] [Related]
9. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.
Lee ST; Li Z; Wu Z; Aau M; Guan P; Karuturi RK; Liou YC; Yu Q
Mol Cell; 2011 Sep; 43(5):798-810. PubMed ID: 21884980
[TBL] [Abstract][Full Text] [Related]
10. Ezh2 represses the basal cell lineage during lung endoderm development.
Snitow ME; Li S; Morley MP; Rathi K; Lu MM; Kadzik RS; Stewart KM; Morrisey EE
Development; 2015 Jan; 142(1):108-17. PubMed ID: 25516972
[TBL] [Abstract][Full Text] [Related]
11. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.
Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C
Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902
[TBL] [Abstract][Full Text] [Related]
12. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract][Full Text] [Related]
13. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.
Zhang B; Liu XX; He JR; Zhou CX; Guo M; He M; Li MF; Chen GQ; Zhao Q
Carcinogenesis; 2011 Jan; 32(1):2-9. PubMed ID: 20952513
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer.
Fang J; Zhang M; Li Q
Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
17. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.
Raaphorst FM; Meijer CJ; Fieret E; Blokzijl T; Mommers E; Buerger H; Packeisen J; Sewalt RA; Otte AP; van Diest PJ
Neoplasia; 2003; 5(6):481-8. PubMed ID: 14965441
[TBL] [Abstract][Full Text] [Related]
18. PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs.
Shan Y; Liang Z; Xing Q; Zhang T; Wang B; Tian S; Huang W; Zhang Y; Yao J; Zhu Y; Huang K; Liu Y; Wang X; Chen Q; Zhang J; Shang B; Li S; Shi X; Liao B; Zhang C; Lai K; Zhong X; Shu X; Wang J; Yao H; Chen J; Pei D; Pan G
Nat Commun; 2017 Sep; 8(1):672. PubMed ID: 28939884
[TBL] [Abstract][Full Text] [Related]
19. The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis.
Yang WS; Chadalapaka G; Cho SG; Lee SO; Jin UH; Jutooru I; Choi K; Leung YK; Ho SM; Safe S; Kim K
Neoplasia; 2014 Dec; 16(12):1059-69. PubMed ID: 25499219
[TBL] [Abstract][Full Text] [Related]
20. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.
Moore HM; Gonzalez ME; Toy KA; Cimino-Mathews A; Argani P; Kleer CG
Breast Cancer Res Treat; 2013 Apr; 138(3):741-52. PubMed ID: 23539298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
